Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis

Company Overview

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Key Stats

• Today's Range: $0.65 to $0.70
• 50-Day Range: $0.54 to $0.71
• 52-Week Range: $0.51 to $2.92
• Volume: 643,146 shs
• Average Volume: 17,214 shs
• Market Capitalization: $26.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Barinthus Biotherapeutics Stock Analysis - MarketRank™

Barinthus Biotherapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 571st out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Barinthus Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Barinthus Biotherapeutics has a consensus price target of $4.00, representing about 513.4% upside from its current price of $0.65.

Amount of Analyst Coverage

Barinthus Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Barinthus Biotherapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of Barinthus Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Barinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.71, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Barinthus Biotherapeutics has recently increased by 85.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Barinthus Biotherapeutics does not currently pay a dividend.

Dividend Growth

Barinthus Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.70% of the stock of Barinthus Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

25.20% of the stock of Barinthus Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 6/05/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BRNS
• Previous Symbol: NASDAQ:BRNS
• CIK: 1828185
• Web: www.barinthusbio.com
• Phone: 44-1865-818-808
• Fax: N/A
• Employees: 107
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Barinthus Biotherapeutics: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +513.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.83%
• Return on Assets: -48.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.05
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $14.97 million
• Price / Sales: 1.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.82 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 40,850,000
• Free Float: 36,478,000
• Market Cap: $26.64 million
• Optionable: N/A
• Beta: -0.40